Our Vision
Fresh Tracks Therapeutics is a clinical-stage pharmaceutical company focused on transforming patient lives through the development of innovative and ground-breaking prescription therapeutics.
When you create Fresh Tracks, you purposefully look to explore beyond. Beyond the obvious. Beyond the conventional. Beyond the imagination.
Our company was built from this belief and, in turn, strives to identify, pursue, and develop next-generation therapeutics that can be groundbreaking in their ability to help millions of people struggling with devastating autoimmune, inflammatory, and other debilitating diseases.
Together, the executive management team and board of directors have a proven track record of leadership across early-stage research, product development, and global commercialization. They have served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first–in–class products that reached iconic status, including Cialis®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide.
We align this expert knowledge and clear vision to explore beyond the limitations of current therapies and accomplish something exceptional.
Leading Through Experience
Meet Our Leaders
With a proven track record, these individuals have come together to lead the company in its development of cutting-edge therapeutics for the treatment of debilitating diseases.
Fresh Strategic Perspectives
Meet Our Board
Consisting of established leaders in the pharmaceutical and biotech space, our Board oversees the company’s strategic vision and mission as we forge ahead with the development of exciting new therapies.
Guiding Innovation
Meet Our Scientific Advisors
We’ve engaged a prestigious Scientific Advisory Board of scientists and clinicians with deep expertise across immunology and inflammation to advise our bold research and development plans.
Pursuing Fresh Opportunities
Partner with Us
We constantly review opportunities to expand our pipeline with novel and differentiated assets. We also welcome those who are interested in partnering with us to efficiently progress our cutting-edge products.